Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions
Anticholinergic Toxicity
Interventions
DRUG

Rivastigmine

Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses

DRUG

Placebo

Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

American Academy of Clinical Toxicology

OTHER

lead

Washington University School of Medicine

OTHER